Clinical trial
A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies
NCT00621244 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 1, 2003
- Completion date
- December 3, 2009
- Enrollment
- 175 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.